



For Professional and Eligible Counterparties /
Institutional / Accredited Investors only.
Not for further distribution

ERCC Professional Repo Market & Collateral Management

LCR & NSFR for Repo – October 2021 workshop

Cecile Retaureau
Global Markets – Head of EMEA Cross-asset Financing Distribution

Disclaimer

This presentation has been prepared by UBS personnel for the purpose of market participant training, based on the standard Basel III framework documentation, as published on the bis.org website by the Basel Committee on Banking Supervision. As such it does not reflect any views from UBS AG and/or any of its affiliates.

This material has been issued by UBS AG and/or any of its affiliates ("UBS" and "we", "us"). The securities, derivatives or other financial instruments described herein ("Instruments") may not be eligible for sale in all jurisdictions or to certain categories of investors. This material is for distribution only under such circumstances as may be permitted by applicable law, rules and/or regulations. All communications between you and us may be monitored. Please see further details as set out under "Country-specific information" below.

Provenance and purpose This material has been prepared by sales or trading personnel and it is not a product of our Research Department and is not intended to recommend, suggest or inform an investment strategy. Opinions expressed may differ from the opinions expressed by our other divisions, including those of the Research Department.

Recipient to exercise own judgment The information contained herein should not be regarded by recipients as a substitute for the exercise of their own judgment. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute the provision of investment advice. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisers to the extent you deem necessary to make your own investment, hedging and trading decisions.

Not an offer to transact This material has been prepared for informational purposes only and is not an offer to buy or sell or a solicitation of an offer to buy or sell any Instrument or to participate in any particular trading strategy. This material is not an official confirmation of terms.

Conflicts of Interest This material may contain proprietary commentary produced in conjunction with our trading desks that trade as principal in the Instruments. This commentary may therefore not be independent from our proprietary interests or those of connected parties which may conflict with your interests. We may have accumulated or may acquire a long or short position in the subject Instrument, or derivative thereof, on the basis of this material prior to its dissemination. We may trade as principal or otherwise act or have acted as market-maker and/or as an execution venue in the Instruments. Instruments may be highly illiquid which may adversely impact the price, spread and speed of execution of orders in those Instruments. Furthermore, we may have or have had a relationship with or may provide or have provided investment banking, capital markets and/or other financial services to the companies associated with the Instruments. We have policies and procedures designed to manage conflicts of interest. In order to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS, we may rely on information barriers. Additional information can be found at "<https://www.ubs.com/global/en/investment-bank/regulatory.html>" and may be made available upon request.

Contents of Material This material is prepared from information believed to be reliable, but we make no representations or warranties, express or implied, and owe no duties (including in negligence) as to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the Instruments, markets or developments referred to in the materials. The information contained in this material is as of the date hereof only and is subject to change without notice. We do not undertake any obligation to update this material. Any prices or quotations contained herein are indicative only and are not for valuation purposes. Past performance is not necessarily indicative of future results.

Statement of Risk The Instruments are not suitable for all investors, and trading in these Instruments is considered risky and is appropriate only for sophisticated investors and in particular any target market identified herein. These Instruments may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates, foreign exchange rates and other market conditions. Some Instruments may be physically settled or cash settled. Options, structured derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Past performance is not necessarily indicative of future results. Prior to buying or selling an option, and for a thorough description of risks relating to options, U.S. investors must receive a copy of 'The Characteristics and Risks of Standardized Options.' You may read the document at <http://www.theocc.com/publications/risks/riskchap1.jsp> or ask your salesperson for a copy.

No Liability To the fullest extent permitted by law, neither we nor any of our directors, employees or agents is liable for any loss (including indirect, special or consequential losses or damages, and even if we have been advised of the possibility of loss) arising out of any person's use of, or reliance upon, the information contained herein.

Securities Act Any Instruments that have not been registered under the United States Securities Act of 1933 may not be offered or sold in the United States except pursuant to an exception from the registration requirements of the Securities Act and applicable state securities laws and in such circumstances as may be permitted by applicable law.

No redistribution or reproduction We specifically prohibit the redistribution or reproduction of this material in whole or in part without our prior written permission and we accept no liability whatsoever for the actions of third parties in this respect. © UBS 2021. All rights reserved.

Executive Summary - Liquidity Ratios

'Repo' plays a crucial role within the financial system.

Understanding the regulatory constraints is therefore key to understand financing products and activities.



Basel III post-crisis reform - Two liquidity standards

Following the failure of many banks to adequately measure, manage and control their liquidity risk in 2008 and in subsequent years, the **Basel Committee on Banking Supervision (BCBS)** introduced two liquidity standards as part of the Basel III post-crisis reforms:

- ✓ The first of these is the **Liquidity Coverage Ratio (LCR)** which enhances banks' short-term resilience
- ✓ The second is the **Net Stable Funding Ratio (NSFR)** which aims to promote resilience over a longer time horizon by creating incentives for banks to fund their activities with more stable sources of funding



Already in place and impacting globally the financing markets

- LCR became a requirement on 1 January 2015, set at 60%, up to 100% on 1 January 2019 for large banks (>\$250bn assets and >\$10bn on-balance-sheet foreign exposure)
- NSFR became effective this year as of 1 July 2021
- **Both LCR and NSFR have had impacts on ways banks are sourcing or deploying liquidity**




Agenda today

1. What are the LCR & NSFR?
2. How are they calculated?
3. What could be possible impacts for banks
4. Case studies based on the Basel III framework publications

Regulation Overview: a more resilient banking sector

Regulations have changed dynamics of Balance-Sheet & Capital and require Banks to optimise their businesses



Basel III - Summary

- ✓ **Capital Requirements** - increased capital requirements for large (G-SIB) banks. Introduction of gone concern capital.
- ✓ **Enhanced Risk Framework** enhanced rule set to capture credit, market and operational risk, including greater constraints on the use of models.
- ✓ **Large Exposure Framework** rules limit risk exposures to counterparties in order to mitigate systemic risk concentrations arising from interlinkages across financial institutions
- ✓ **Leverage Ratio** ensures that Tier 1 Capital is 3% of Leverage exposure (total assets and certain off balance sheet items). G-SIB banks have to meet a minimum of 5%
- ✓ **Liquidity Coverage Ratio** (2015-2019) ensures that banks maintain an adequate level of liquid assets to survive a 30-calendar day acute stress scenario
- ✓ **UMR Phase 5 & 6** - final phase of UMR requires both counterparties to swap contract to exchange initial margin subject to materiality thresholds
- ✓ **The Net Stable Funding Ratio** (2021) designed to influence the structure of funding by creating incentives for banks to fund assets not readily saleable with stable funding

Regulatory outlook

Basel 4 – (2022) Basel's upgraded capital framework enhancements to the rules, significantly raising the bar on capital, risk frameworks and, leverage ratio



Section 1

LCR – Liquidity Coverage Ratio

What is LCR?



Background:

- LCR is **set by the Basel Committee** for Banking Supervision created as part of the **Basel III post-crisis reform**

When and why has it been introduced:

- **Before 2007 crisis**, Banks were inclined to expand their B/S by **relying on relatively cheap and abundant short term funding**.
- The LCR is designed to ensure that banks hold **a sufficient reserve of liquid assets to survive a short term liquidity stress** over a period of 30 calendar days.
- Short term stress means: firm-specific, broader industry or market liquidity stress events
- Published in **January 2013** and reviewed as of 15 December 2019
- Implemented fully as of **1 January 2019**

Where does it apply:

- LCR is an **international standard** which applies globally
- **Each region/jurisdiction have implemented their own version** so there are differences in term of content and timing
- **Some banks have more stringent definitions than others**

LCR Calculation

LCR*

LCR: Liquidity Coverage requires banks to hold a stock of HQLA at least as large as expected total net cash outflows over the stress period

$$\frac{\text{Stock of High-Quality Liquid Assets (HQLA)}}{\text{Net cash outflows over the next 30 calendar days}} \geq 100\%$$

This ratio should be equal to **at least 100%**, on an ongoing basis

HQLA: HQLA are cash or assets that can be converted into cash easily through liquidation without significant loss of value. There are 3 levels of HQLA: Level 1, Level 2a and Level 2b

Cash outflows: total expected cash outflows minus total expected cash inflows in the specified stress scenario for the subsequent 30 calendar days. Please note that a 75% cap on outflows is applied to the inflows calculation
= expected cash outflows – min (expected inflows; 75% of expected outflows)

*At end-June 2020, EU banks' average LCR stood at 166% and no bank reported LCR levels below 100%***

*Source: https://www.bis.org/basel_framework/chapter/LCR/40.htm

**Source: <https://www.eba.europa.eu/eba-updates-its-report-liquidity-measures-and-confirms-banks%E2%80%99-solid-liquidity-position>

LCR numerator: High Quality Liquid Assets (HQLA)

HQLA can be both **easily and immediately converted into cash** at little or no loss in value in case of market turbulence, ideally central bank eligible.

All assets in the stock must be **unencumbered and operationally monetizable**

*Each regulator institution can apply a more stringent definition

Level 1 assets	HC
Cash & Central Bank Reserves	0%
Domestic sovereign or central bank debt for non 0% risk-weighted sovereigns (e.g., Bund, OAT, UST, Gilt, Swiss Govt)	
Liquid Marketable securities assigned a 0% risk weight	
Level 2A assets (maximum 40% of HQLA pool)	HC
Marketable securities issued by sovereigns, central banks, Public Sector Entities and MDBs assigned a 20% risk weight	15%
Non financial corporate debt securities rated AA- or higher	
Covered bonds rated AA- or higher	
Level 2B assets (maximum 15% of HQLA pool)	HC
RMBS (rated AA and higher), Corporate Debt (non-financial, rated A+ to BBB-)	25%
Equity shares (non-financials, exchange traded, major index)	50%
All Others	HC
Corporate Debt (below BBB-) and all Financials bonds, even investment grade	100%

Stock of HQLA = Level 1 + Level 2a + Level 2b – adjustment for 15% cap – adjustment for 40% cap

Case Studies: comparing HQLA types




Product covered

Repo, financing swap
Collateral exchange

Case 1 - Reverse repo

Trade: Reverse repo under GMRA
Collateral: B-rated corporate bonds = **non-HQLA**
Tenor: 6-months
Counterparty: Hedge Fund
Bank A is downgrading its LCR for 5 months


Diagram



Case 2 – Financing TRS

Trade: Financing TRS under ISDA/CSA
Collateral: benchmark GC Gilt = **L1 HQLA**
Tenor: 3-years
Counterparty: UK Asset Manager
No impact on Bank A's LCR for the whole duration


Diagram



Case 3 – Collateral downgrade

Trade: Collateral exchange under GMSLA
Loaned Securities: OAT = **Level 1 HQLA**
Collateral: GC equity from tradable index = **L2B HQLA**
Tenor: 12-months
Counterparty: Bank
Bank A is downgrading its LCR by 50% for 11-months

Diagram



Did you know?



LCR is agnostic when it comes to trade formats: repo, securities lending, on- or off-balance sheet derivatives

Case Studies: evergreen and extendible tenors



Product covered


Repo

Collateral exchanges

Case 4 - Reverse repo < 31-days

Trade: Reverse repo under GMRA
 Collateral: B-rated corporate bonds = **non-HQLA**
 Tenor: **29-day evergreen**
 Counterparty: Hedge Fund
 Cash outflow but inflow within 31-days
No impact on Bank A's LCR for the whole duration


Diagram



Case 5 – Collateral upgrade

Trade: Collateral exchange under GMSLA
 Loaned Securities: US Treasuries = **HQLA Level 1**
 Collateral: B-rated corporate & SPACs = **non-HQLA**
 Tenor: **1 year evergreen**
 Counterparty: Insurance Company
Bank A is upgrading LCR up until the trade evergreen feature is called, then LCR benefit will remain for 11 months


Diagram



Case 6 – back-to-back Collateral exchanges

Trade: up and-downgrades under GMSLA
 Bank A sources from Sec Lender a ESM bond for 10 bps vs Triparty IG set (incl. Corp/MBS) and lend to Bank B for 50 bps
 Loaned Securities: EUR denominated ESM bond (**L1 HQLA**)
 Collateral: AAA EUR RMBS, ECB eligible = **L2B HQLA**
 Tenor: **18 months versus 2-1-2-month extendible**
No impact on Bank A's LCR as long as the 2-1-2 trade is mutually extended monthly

Diagram



The implementation of LCR has led to the increase in extendible and evergreen tenors on the street

In a 29-day evergreen tenor: the trade will extend automatically every day by 1 more day (calendar), or equivalently, both parties can call the trade with 29 calendar day-notice

In a 2-1-2-month extendible tenor: parties can mutually agree to extend the trade every month by 1 more month (calendar). If not extended, the trade will terminate at its original tenor (eg. in one month)



Did you know?



Section 2

NSFR – Net Stable Funding Ratio

What is NSFR?



Background:

- NSFR is **set by the Basel Committee** for Banking Supervision created as part of the **Basel III post-crisis reform**

Why and when has it been introduced:

- **Before 2007 crisis**, Banks were inclined to expand their B/S by **relying on relatively cheap and abundant short term funding**.
- The aim of **NSFR** is to **limit excessive reliance of Banking system to short and unstable funding sources**.
- Published in **October 2014** and reviewed as of 15 December 2019
- Implemented fully as of **1 July 2021**

Where will it apply:

- NSFR is an **international standard** which applies in globally
- **Each region/country have implemented their own version** so there are differences in term of content and timing
- For instance: The EU implemented the NSFR via the Capital Requirements Regulation II, which was published in the EU Official Journal on 7 June, 2019. CRR II entered into force on 27 June 2019 and NSFR became binding on 27 June 2021

NSFR Calculation

NSFR

NSFR: Net Stable Funding Ratio is defined as the available stable funding relative to the amount of required stable funding.

$$\frac{\text{Available Stable Funding (ASF)}}{\text{Required Stable Funding (RSF)}} \geq 100\%$$

This ratio should be equal to **at least 100%**, on an ongoing basis
NSFR is balance-sheet/LRD driven: trades with IFRS on-B/S exposures will likely have a NSFR impact

ASF: portion of **capital & liabilities expected to be reliable** over time horizon, which extends to 1-year

RSF: **amount of stable funding required** and is a function of liquidity characteristics and residual maturities of the various assets held as well as those of its off-balance sheet exposures

The **NSFR uses a balance sheet approach** to calculate '*available stable funding*', which must be at least equal to or greater than '*required stable funding*'

Available Stable Funding (ASF)

ASF measures the stability of an institution's funding sources

Think Bank's "Liabilities": who Bank borrows from?

ASF

- ASF is split into **5 categories** at which each **applies a factor**
- Each category is linked to **maturity** and the **probability of the funding provider to withdraw their funding**
- **Total ASF = Sum of each category multiplied by the applicable factor**

ASF Factors

100%

95%

90%

50%

0%

Capital & Liabilities
Long Tenor
High Stability

Capital & Liabilities
Short Tenor
Low Stability

ASF: what will matter most ?

1. **Funding Tenor:** Longer term liabilities considered more stable than short-term liabilities, favouring funding tenors above 1 year.
2. **Funding Counterparty:** Funding provided by certain counterparty considered more stable (Corporates more stable than Banks)
3. **Asset Quality & Liquidity:** Good quality assets do not need to be wholly financed with stable funding

Available Stable Funding (ASF)

ASF will vary with maturity and bank funding providers

Key notes:

- ❖ **Collateral upgrade / GMSLA** (eg Bank sources HQLA vs Equity) does not create a new liability, off-B/S) so **will not create any ASF**
- ❖ **Open repo:** 0% ASF
- ❖ NSFR led to change in market eg. with more frequent **Callable debt issuances (eg. 4NC3 FRNs)** from Financial Institutions or increased concentration in **retail deposits** (although often an expensive solution)

Factor	Residual tenor	Bank get funding from:	Liability type / Balance-sheet items	
100%	All	n.a	Capital	Regulatory Capital (excluding Tier 2 instruments <1y) Capital instruments above >1y
	Above 1y	Any counterparty	Funding	Liability with maturity >=1 year (eg. Repo > 1y) (eg. Financial debt 4y callable when residual tenor <1y)
95%	Below 1y	Small Business & Retail customers	Deposit	Term deposits
90%	Below 1y			Less stable non-maturity deposit
50%	Below 1y	Sovereign Public sector entity "PSE" Multilat and National Devt Banks Non-Financial Corporate	Funding	Liability with maturity <1 year (eg. 95-day Repo with PSE or deposit from Corp)
	6 months to 1-year	Central Bank Financial Institutions (Bank , AM/HF, InsCo, Pension, Financial Corp...)	Funding	Liability with maturity 6m to 1 year (eg. 6-month evergreen Repo with Bank)
0%	Other	Any counterparty	Funding	Other Liability not mentioned above or with no maturity (eg. 1 week repo with Hedge Fund or Open repos)
	All	Any counterparty	Derivatives	Derivatives MTM will not create any ASF if net Liability > 0

Required Stable Funding (RSF)

RSF is the amount of **stable funding required to cover its on & off-B/S assets**

Think Bank's "Assets": what does Bank invest into?
Who Bank lends to?

RSF

- The RSF is split into **8 categories** at which each applies a factor
- Each RSF factor intend to approximate the amount level of funding needed to **assuming an LT asset won't easily be refinanced > 1year** without a cost.
- Each category is linked to the transaction residual **maturity** and **liquidity value of the collateral**. The **counterparty type** should also be taken into account to determine the RSF factor
- Total RSF = **Sum of each category x by the applicable factor + the off B/S activity x applicable factor**

RSF Factors

0%

5%

10%

15%

50%

65%

85%

100%

Capital & Liabilities
High Liquidity

Capital & Liabilities
Low Liquidity

RSF: what will matter most ?

1. **Funding Tenor:** Longer term assets will be detrimental, avoiding funding tenors above 1 year, and even 6-months to some extent
2. **Borrower Counterparty:** lending to Financials will require less stable funding than lending to a Sovereign or PSE
3. **Asset invested into and if encumbered**

Required Stable Funding (RSF)

RSF will vary with **maturity, investment and borrowers** as well as **encumbrance of assets** invested into

Key notes:

- ❖ **asymmetry between regulators:** impacting repo and cash trading (example of Open repo or Government bond repo and cash investment)
- ❖ **asymmetry between Public/Govt and FI:** lending 3-month to a PSE will require more stable funding than the same with Bank/Hedge Fund
- ❖ **any lending above 1y will use 100% of RSF** whereas it is a repo versus Govie, IG, HY or CLO

EU/ US**	CH/ Basel	Resid. tenor	Asset / Balance sheet item	with Counterparty	Example trade
	0%	n.a	Cash	n.a	Cash holding
		Below 6m	Reserves and claims	Central Banks	3-month Reverse repo vs UST with SNB
0%	5%	All	Unencumbered HQLA Level 1	All	Outright Purchase of OAT
0-5%	10%	Below 6m	Unencumbered loan vs HQLA 1 (rehyp)	Fin Institutions	3-month Reverse repo vs UST with HF
5%	15%	All	Unencumbered HQLA Level 2A	All	Outright Purchase of 2A Covered bond
		Below 6m	Unencumbered loan vs other assets	Financial Institution	3-month Reverse repo vs Corp with Bank
	50%	All	Unencumbered HQLA Level 2B	All	Outright Purchase of 2B Equity or RMBS
		[6m;1y[Encumbered HQLA	All	Purchase of a OAT and lending it in 6m repo
		[6m;1y[Loan	To Fin Institution or CBs	6-month Reverse repo on EM with AM
		Below 1y	Other assets/Loans	To Non-Fin Corporate, Retail, Sov, PSE	3-month Reverse repo on Corp with PSE
	65%	Above 1y	Unencumbered Resi Mtge RW* <=35%	All	Purchase of portfolio of eligible Resi Mtges
		Above 1y	Unencumbered Loans with RW <= 35%	All excl. Fin Institution	
	85%		Initial Margin / Cash to the CCP		Derivatives IM / CCP default fund
		Above 1y	Unencumbered Loans RW > 35%	All excl. Fin Institution	
		Above 1y	Unencumbered Non-HQLA assets, exchange traded Equity, Physical Commodities	All	Purchase of HY Corp or non HQLA Equity
	100%	Above 1y	Encumbered Assets	All	Purchase OAT and lend it for 3y
		Above 1y	NPLs, Other Loans/Assets not incl. above, non exchange traded equity	All	3y reverse repo on Gilt with Bank
			Net MTM of Derivatives (if Asset > Liab)		Open repo subj to jurisdiction
			20% of Derivatives liability calculated as Replacement Cost		Net VM posting create 100% RSF
					where derivatives has <0 value

*RW = Risk Weight under standardised approach

**EU/US implementation is different at least until 2025

NSFR summary

Banks constrained by NSFR would have to **move to longer term funding** (e.g. >6m) potentially affecting demand in short dated money markets

Asymmetries will lead to banks **choosing the combination of counterparty type and residual maturities** which best fits the NSFR construct

...and might lead to spread **dislocation in repo market and other financing activities** depending on each bank's internal cost or premium for NSFR usage

- If you lend 3-month cash to Bank and you hedge with 1 month borrow from a Corporate -> you can create NSFR
- If you lend 3-month to a HF and you hedge with a 3-month borrow from a bank -> you will degrade your NSFR

Residual Maturity / Counterparty Type	< 6m		[6m ; 1y[> 1y	
	ASF	RSF	ASF	RSF	ASF	RSF
Sovereign / PSE	50%	50%	50%	50%	100%	65%/ 85%
Non-Fin Corp	50%	50%	50%	50%	100%	65%/ 85%
Central Banks	0%	0%	50%	50%	100%	100%
Banks / Fin. Institution	0%	10% /15%	50%	50%	100%	100%
Retail / Small Business	0%	50%	50%	50%	100%	65%/ 85%

Optimal combinations

Tenor	Factor	ASF – borrow \$ from:	Factor	RSF – deploy \$ to:
<6m	[50%]	Sov, PSE, Non-Fin Corporate	[0%]	Central Bank (CB)
	[0%]	CB, Banks, Other Fin, Retail	[10%/15%]	Banks, Other Fin
[6m;1y[[0%]	CB, Banks, Other Fin, Retail	[50%]	Sov, PSE*, Non-Fin Corpo
	[50%]	All	[50%]	All
>=1y	[100%]	All	[65%/85%]	Sov, PFE, Non-Fin Corpo, Retail
			[100%]	Banks, Other Fin

Case Studies: comparing counterparties & collateral




Product covered

Repo

Case 1 - Reverse repo on non-HQLA

Trade: Reverse repo under GMRA
Collateral: B-rated corporate bonds = **non-HQLA**
Tenor: **13-12-13-month extendible**
Counterparty: Bank/Financial Institution
RSF = 100% (>1y lending to financial institution)
Bank A will need to source 100% ASF to avoid NSFR drag


Diagram



Case 2 – Reverse repo on HQLA 1

Trade: Reverse repo under GMRA
Collateral: Benchmark Gilts = **HQLA Level 1**
Tenor: **7 months**
Counterparty: Asset Manager
RSF = 50% (6m-1y lending to financial institution)
Bank A will need to source 50% ASF to avoid NSFR drag


Diagram



Case 3 – Reverse repo with Central Bank

Trade: Reverse repo under GMRA
Collateral: AAA EUR RMBS, EGB eligible = **HQLA Level 1**
Tenor: **3 months**
Counterparty: Central Bank
RSF = 0% (claims to central banks with maturity < 6months)
No impact on Bank A's NSFR

Diagram



In May 2021, Eurex launched NSFR efficient Evergreen repo products (185d and 370d) to help banks better meet their stable funding requirements*

NSFR is asymmetric in terms of jurisdictions and type of counterparty Bank faces.

NSFR does not recognize the same value to HQLA L1 as LCR.

*Source: Eurex Briefing Note 01/2021



Did you know?

Case Studies: LRD friendly transactions




Product covered

Collateral exchange
Derivatives

Case 4 – Financing TRS

Trade: Financing TRS under ISDA/CSA
Reference Obligation: CHF Swiss Government Bonds
Tenor: **2-years**
Counterparty: Insurance Company
RSF = 100% (trade requalified in reverse repo > 1y to Financials)
Bank A will need to source 100% ASF to avoid NSFR drag


Diagram



Case 5 – Outright purchase & collateral downgrade

Trade: **Bank A buy a 5y-UST outright and re-use it in collateral downgrade** for yield enhancement under GMSLA
Collateral: UST, then onward lent vs Emerging Market Corps
Tenor: **3 years**
Counterparty: EM Bank
RSF = 100% (trade encumbers UST for more than 1y)
Bank A will need to source 100% ASF to avoid NSFR drag


Diagram



Case 6 – back-to-back collateral exchanges

Trade: up and-downgrades under GMSLA
Loaned Securities: OAT
Collateral: Mix of ABS and CLOs
Tenor: **3 year versus 1 year evergreen**
No impact on Bank A's NSFR (off-B/S transaction under IFRS)

Diagram



NSFR is driven by the “IFRS” balance-sheet: LRD-friendly transactions will be mores lightly impacted by NSFR

A fully off-B/S TRS would only attract NSFR on its MTM



Did you know?



Useful public information

ICMA ERCC "Impacts of the Net Stable Funding Ratio on Repo and Collateral Markets"

- <https://www.icmagroup.org>

BIS website - NSFR & LCR relevant BCBS publications

- https://www.bis.org/basel_framework/standard/LCR.htm
- https://www.bis.org/basel_framework/standard/NSF.htm

EBA publications

- <https://www.eba.europa.eu/regulation-and-policy/implementing-basel-iii-europe>

FINMA publications (Circular 2015/02)

- <https://www.finma.ch/en/documents/>

Federal Reserve & Office of the Comptroller of the Currency websites

- <https://www.federalreserve.gov/supervisionreg/basel/basel-default.htm>
- <https://www.occ.gov/topics/supervision-and-examination/capital-markets/balance-sheet-management/liquidity/liquidity-coverage-ratio-final-rule.html>
- <https://www.occ.gov/news-issuances/bulletins/2021/bulletin-2021-9.html>

Country-specific information

Except as otherwise specified herein, these materials are distributed to professional clients only, and are not suitable for retail clients. For further important country-specific information, please see the following link: <https://www.ubs.com/global/en/investment-bank/us-sales/tradingcountry-specific.html>

EMEA Europe Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) Rules and according to MIFID) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is a Societas Europaea registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Frankfurt am Main under HRB 107046. Registered office: Bockenheimer Landstrasse 2-4, OpernTurm, 60306 Frankfurt am Main. UBS Europe SE is authorised and regulated by the German federal financial supervisory authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and the European Central Bank (ECB). **France** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities France S.A. UBS Securities France S.A. is regulated by the Autorite de Controle Prudentiel et de Resolution (ACPR) and the Autorite des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document and/or these materials, they are also deemed to have been prepared by UBS Securities France S.A.. **Spain** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities Espana SV, SA. UBS Securities Espana SV, SA is regulated by the Comision Nacional del Mercado de Valores (CNMV).

United Kingdom Prepared and distributed by UBS AG, London Branch. UBS AG, London Branch is authorised by the Prudential Regulation Authority (PRA) and regulated by the Financial Conduct Authority (FCA) and the PRA. **Germany, Luxembourg, the Netherlands, Belgium and Ireland** To the extent these materials relate to products other than cash equities or cash bond trading, prepared and distributed by UBS AG, London Branch. **Poland** These materials are distributed by UBS Europe SE (spółka europejska) Oddział w Polsce regulated by the Polish Financial Supervision Authority only to institutional investors in Poland. The information contained herein does not apply to, and should not be relied upon by retail clients. **Switzerland** These materials are intended for distribution in Switzerland by UBS AG to qualified investors pursuant to Art.10 of the Swiss Federal Act on Collective Investment Schemes (CISA) as, for example, institutional investors only. **Turkey** Prepared and distributed by UBS AG, London Branch. **Russia** Prepared and distributed by UBS Bank (OOO). No non-Russian securities or derivatives are offered within Russia to anybody except for investors qualified under Russian law. **South Africa** UBS South Africa (Pty) Limited (Registration No. 1995/011140/07) is an authorised user of the Johannesburg Stock Exchange (JSE) and an authorised Financial Services Provider (FSP 7328). **UAE/Dubai** These materials are distributed by UBS AG Dubai Branch and are only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon these materials. These materials are not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE Securities and Commodities Authority. **Saudi Arabia** These materials have been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Israel** UBS AG and its affiliates incorporated outside Israel are not licensed under the Investment Advice Law. These materials are being issued only to and/or are directed only at persons who are Sophisticated Investors within the meaning of the Israeli Securities Law and these materials must not be relied or acted upon by any other persons.